Abiopharma

🔍 Lin Lauren (Executive)

Company: WEALTHFRONT CORP (WLTH)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 12,500 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 156,075.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 9,375 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 165,450.00 | transaction_form_type: 4
• Acquired 4,687 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 170,137.00 | transaction_form_type: 4
• Acquired 12,847 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 182,984.00 | transaction_form_type: 4
• Sold 20,052 shares of Common Stock at $8.8 per share (Direct)
  Date: 2026-06-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 162,932.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 12,500 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5
• Sold 9,375 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 46,875.00 | transaction_form_type: 4 | Footnotes: F3, F6, F5
• Sold 4,687 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 42,188.00 | transaction_form_type: 4 | Footnotes: F3, F7, F5
• Sold 12,847 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 167,010.00 | transaction_form_type: 4 | Footnotes: F3, F8, F5

Footnotes:

• F1: Includes 2,385 shares of Class A Common Stock acquired by the reporting person in one or more transactions with Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
• F2: The transaction represents the number of shares of Common Stock withheld by the Issuer to satisfy tax withholding liabilities in connection with the net settlement of restricted stock units.
• F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• F4: The award vested or vests as to 1/16 of the total award quarterly on the fifteenth calendar day of March, June, September, and December, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on March 15, 2023.
• F5: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
• F6: The award vested or vests as to 1/16 of the total award quarterly on the fifteenth calendar day of December, March, June, and September, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on December 15, 2023.
• F7: The award vested or vests as to 1/16 of the total award quarterly on the fifteenth calendar day of December, March, June, and September, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on December 15, 2024.
• F8: The award vested or vests as to 1/16 of the total award quarterly on the fifteenth calendar day of December, March, June, and September, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on December 15, 2025.